Arab World vs Togo: Access to anti-retroviral drugs, female
Arab World
48.4%
in 2024
Togo
96.0%
in 2024
Arab World rank
16th
Togo rank
14th
Access to anti-retroviral drugs, female over time
- Arab World
- Togo
How they compare
Togo currently reports 96.0% against 48.4% in Arab World, a difference of 47.6%.
That makes Togo's figure about 2.0 times Arab World's.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Arab World ahead.
Arab World ranks 16th and Togo ranks 14th of 19 groups.
Across the 3 decades both report, Arab World averaged higher in 1 and Togo in 2.
Head to head by decade
| Decade | Arab World | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.7% | 4.6% | 0.1% | Arab World |
| 2010s | 28.0% | 51.6% | 23.6% | Togo |
| 2020s | 46.9% | 91.2% | 44.3% | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Arab World or Togo?
- Togo, at 96.0% against 48.4% in Arab World as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Arab World and Togo?
- 47.6%, with Togo ahead.
- How many years of comparable data are there for Arab World and Togo?
- 25 years are reported by both, from 2000 to 2024.
- How do Arab World and Togo rank globally for access to anti-retroviral drugs, female?
- Arab World ranks 16th and Togo ranks 14th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.